^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Basal Cell Carcinoma
    Drug:Odomzo (sonidegib) (Hedgehog cell-signalling pathway inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    06/09/2020
    Excerpt:
    Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/13/2019
    Excerpt:
    ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/24/2019
    Excerpt:
    Basal cell skin cancer: Principle of systemic therapy…Systemic therapy options included: Hedgehogpathway inhibitors (ie, vismodegib, sonidegib).